Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 114

Sort by

Sort Order Select

Journal Articles

What's new in the prevention and treatment of cancer-associated thrombosis?

Miriam Kimpton, Marc Carrier

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 158–166.

https://doi.org/10.1182/hematology.2019000023

Published: 2019

Journal Articles

Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models

Yohei Hisada, Nigel Mackman

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 182–186.

https://doi.org/10.1182/hematology.2019000025

Published: 2019

Journal Articles

Is there a role for low-dose DOACs as prophylaxis?

Alexander T. Cohen, Beverley J. Hunt

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 187–193.

https://doi.org/10.1182/hematology.2019000026

Published: 2019

Journal Articles

Update from the clinic: what’s new in the diagnosis of cancer-associated thrombosis?

Erica A. Peterson, Agnes Y. Y. Lee

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 167–174.

https://doi.org/10.1182/hematology.2019000024

Published: 2019

Journal Articles

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician’s view

Andra H. James

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 148–151.

https://doi.org/10.1182/hematology.2019000071

Published: 2019

Journal Articles

What we have learned about direct oral anticoagulant reversal

Deborah M. Siegal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 198–203.

https://doi.org/10.1182/hematology.2019000072

Published: 2019

Journal Articles

Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding

Miriam Kimpton, Deborah M. Siegal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 204–208.

https://doi.org/10.1182/hematology.2019000074

Published: 2019

Journal Articles

Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome

Michelle Petri

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 415–420.

https://doi.org/10.1182/hematology.2019000046

Published: 2019

Journal Articles

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist’s view

Margaret V. Ragni

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 152–157.

https://doi.org/10.1182/hematology.2019000022

Published: 2019

Journal Articles

Is there a role for immunosuppression in antiphospholipid syndrome?

Ecem Sevim, Rohan Willis, Doruk Erkan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 426–432.

https://doi.org/10.1182/hematology.2019000073

Published: 2019

Journal Articles

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

Hanny Al-Samkari, Jean M. Connors

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 71–79.

https://doi.org/10.1182/hematology.2019000369

Published: 2019

Journal Articles

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

Brady L. Stein, Karlyn Martin

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 397–406.

https://doi.org/10.1182/hematology.2019001318

Published: 2019

Journal Articles

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

Katsue Suzuki-Inoue

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 175–181.

https://doi.org/10.1182/hematology.2019001388

Published: 2019

Journal Articles

Inherited hemolytic anemia: a possessive beginner’s guide

Narla Mohandas

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 377–381.

https://doi.org/10.1182/asheducation-2018.1.377

Published: 2018

Journal Articles

Anticoagulating patients with high-risk acquired thrombophilias

Leslie Skeith

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 439–449.

https://doi.org/10.1182/asheducation-2018.1.439

Published: 2018

Journal Articles

Management of thrombosis in children and neonates: practical use of anticoagulants in children

Paul Monagle, Fiona Newall

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 399–404.

https://doi.org/10.1182/asheducation-2018.1.399

Published: 2018

Journal Articles

Adult and pediatric mechanical circulation: a guide for the hematologist

Lisa Baumann Kreuziger, M. Patricia Massicotte

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 507–515.

https://doi.org/10.1182/asheducation-2018.1.507

Published: 2018

Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.

https://doi.org/10.1182/asheducation-2017.1.480

Published: 2017

Journal Articles

Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)

Rachael Hough, Ajay Vora

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 251–258.

https://doi.org/10.1182/asheducation-2017.1.251

Published: 2017

Journal Articles

When can we stop anticoagulation in patients with cancer-associated thrombosis?

Agnes Y. Y. Lee

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 128–135.

https://doi.org/10.1182/asheducation-2017.1.128

Published: 2017

NARROW

What's new in the prevention and treatment of cancer-associated thrombosis?

Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models

Is there a role for low-dose DOACs as prophylaxis?

Update from the clinic: what’s new in the diagnosis of cancer-associated thrombosis?

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician’s view

What we have learned about direct oral anticoagulant reversal

Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding

Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome

Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist’s view

Is there a role for immunosuppression in antiphospholipid syndrome?

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin

Inherited hemolytic anemia: a possessive beginner’s guide

Anticoagulating patients with high-risk acquired thrombophilias

Management of thrombosis in children and neonates: practical use of anticoagulants in children

Adult and pediatric mechanical circulation: a guide for the hematologist

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)

When can we stop anticoagulation in patients with cancer-associated thrombosis?

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only